ONC_AALL0932

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

This partially randomized phase III trial studies different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia or B-lineage lymphoblastic lymphoma that is found only in the tissue or organ where it began (localized). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
Eligibility:
Age: 1 year to 30 years
B-ALL patients must be enrolled on AALL08B1 prior to treatment
B-ALL patients must have an initial white blood cell count <50,000/ul
Patients must have newly diagnosed Standard Risk B-ALL or B-LLy
Patients with Down Syndrome are also eligible.
Phase III
NCT01190930
Cancer
Hematologic
Brenda Wittman, M.D.
COG (Childrens Oncology Group)
Katie Jones
  • Alaska Research
  • Providence Alaska Medical Center